resiquimod has been researched along with Black Fever in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ainslie, KM; Bachelder, EM; Brackman, DJ; Gupta, G; Papenfuss, TL; Peine, KJ; Satoskar, AR | 1 |
| Birnbaum, R; Bruhn, KW; Craft, N; Erfe, MC; Haskell, J; Quanquin, N; Quant, C | 1 |
| Ainslie, KM; Bachelder, EM; Duong, AD; Gupta, G; Peine, KJ; Satoskar, AR; Sharma, S; Wyslouzil, BE | 1 |
3 other study(ies) available for resiquimod and Black Fever
| Article | Year |
|---|---|
Liposomal resiquimod for the treatment of Leishmania donovani infection.
Topics: Administration, Intravenous; Animals; Antiprotozoal Agents; Bone Marrow; Disease Models, Animal; Imidazoles; Interferon-gamma; Interleukin-10; Leishmania donovani; Leishmaniasis, Visceral; Leukocytes, Mononuclear; Liposomes; Liver; Mice; Mice, Inbred BALB C; Parasite Load; Spleen; Treatment Outcome | 2014 |
Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.
Topics: Administration, Topical; Animals; Antiprotozoal Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemoprevention; Disease Models, Animal; Female; Granulocytes; Imidazoles; Leishmaniasis, Visceral; Liver; Mice, Inbred BALB C; Spleen | 2014 |
Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.
Topics: Animals; Cell Line; Cricetinae; Drug Carriers; Imidazoles; Leishmania donovani; Leishmaniasis, Visceral; Mesocricetus; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Polymers; Toll-Like Receptors | 2013 |